U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)
22.7.2019 14:00:00 EEST | Business Wire | Press release
The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005154/en/
Ronald L. Melnick, PhD, who led the design of the large $30 million NIH/NTP Animal Study, which showed Radio Frequency Radiation emitted by cell phones and wireless devices causes cancer, confirms that the previously held assumption the radiation cannot cause cancer, or other adverse health effects, is wrong. (Photo: Business Wire)
There is particular urgency at this time as new antennas will be densely located throughout residential neighborhoods using much higher frequencies, with greater biologically disruptive pulsations, more dangerous signaling characteristics, plus transmitting equipment on, and inside, homes and buildings. The Advisors to The Appeal recommend UNEP seriously weigh heavily the findings of the independent, non-industry associated EMF science.
See video of spokesperson for The Appeal , the late Martin Blank, Ph.D., of Columbia University, and read the recent letter to the UNEP and the Appeal.
The Advisors to the International EMF Scientist Appeal - Annie Sasco, MD, Dr.PH., Henry Lai, Ph.D., Joel Moskowitz, PhD., Ronald Melnick, Ph.D. and Magda Havas, Ph.D. - call upon the UNEP to be a strong voice for the total environment of the planet, and an effective catalyst within the United Nations with regards to the biological and health effects of electromagnetic pollution.
In the letter to UNEP, Magda Havas, Ph.D., Professor Emeritus, Trent University School of the Environment, Canada, details serious effects on plants, insects and wildlife from electromagnetic fields that are well documented in the scientific literature.
Ronald Melnick, Ph.D., Advisor to The Appeal and former scientist at the U.S. National Toxicology Program (NTP) within the National Institutes of Health (NIH), who managed the design and development of the NTP's recently published $30 million animal study showing a clear link between radio frequency radiation (RFR) and cancer, states: “Results from the NTP study show that the previously held assumption that radiofrequency radiation cannot cause cancer or other adverse health effects is clearly wrong.” Policymakers the world over should take note.
See International EMF Scientist Appeal and Letter to UNEP (June 25, 2019)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005154/en/
Contact information
Elizabeth Kelley, M.A., Director
EMFscientist.org
info@EMFscientist.org
1-520-912-4878
Joel M. Moskowitz, Ph.D.
School of Public Health, UC Berkeley
jmm@berkeley.edu
1-510-643-7314
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a
Boomi and Red Hat Collaborate on Production-Ready Agentic AI13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Red Hat, the world’s leading provider of open source solutions, today announced a strategic collaboration to deliver a single, integrated stack for deploying agentic AI at scale. For many organizations, building production AI today means assembling numerous disconnected vendor choices spanning agent builders, orchestration tools, governance platforms, model providers, integration middleware, and security infrastructure, which can lead to data leaks and unpredictable costs. Boomi and Red Hat are working together to simplify AI innovation for customers by bringing together Boomi’s Agentstudio with the enterprise-grade power of Red Hat AI. This makes it easier for organizations to build agents that solve real business problems while supporting corporate standards for sovereignty, infrastructure flexibility, and performance reliability. Together, Boomi and Red Hat are collaborating to deliver an integrated solution designed to simplify how org
Lenovo Named a Leader and Star Performer in Mid-Market Digital Workplace Solutions Assessment by Everest Group13.5.2026 16:00:00 EEST | Press release
Lenovo’s ability to help mid‑market organizations reduce IT support costs, accelerate time-to-value, and improve workforce productivity at scale has earned recognition as a Leader and Star Performer in Everest Group’s 2026 Digital Workplace Services PEAK Matrix® Assessment for Mid‑Market Enterprises. Lenovo’s Digital Workplace Solutions (DWS) enable customers to improve speed, cut costs, and elevate employee experiences, helping new employees reach productivity up to 50% faster, increasing employee satisfaction by 30%, lowering end-user support costs by up to 30%, and proactively resolving up to 40% of issues to minimize downtime and business disruption1. Lenovo delivers these results by uniquely integrating device, services, and intelligence into a single, scalable delivery model built for the mid‑market. Through lifecycle services delivered at global scale, AI‑powered automation and insights from Lenovo xIQ, and consumption‑based flexibility through TruScale DaaS, customers gain cont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom